$HTBX Heat Biologics, Inc. Chief Medical Advisor Dr George Peoples tells Proactive the Durham, North Carolina-based clinical-stage biopharmaceutical company revealed positive interim data from its Phase 2 trial of HS-110, in combination with Bristol-Myers Squibb's OPDIVO to treat advanced non-small cell lung cancer. Peoples says the data suggests the addition of Heat's allogeneic cell-based therapy compared to previous published data of OPDIVO alone, doubled the median survival of patients.
3
11
11 Likes